Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy

Key Points The Khorana score did risk-stratify cancer patients according to 6-month risk of VTE, but only for some cancer types. Absolute risk estimates were lower than previously reported, questioning the benefit of ambulatory thromboprophylaxis in cancer patients.